|Bid||246.62 x 100|
|Ask||349.90 x 100|
|Day's Range||333.93 - 343.31|
|52 Week Range||244.28 - 348.84|
|PE Ratio (TTM)||22.19|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
Biogen’s stock rallies to 2-year high after two analysts raise their ratings to buy and their price targets to at least $400.
The Dow (^DJI) pierces 23,000 after strong earnings beats by UnitedHealth (UNH) and Johnson & Johnson (JNJ), but quickly retreats and settles into a low volume trading range for the balance of the day. Plus, Gary Cohn speaks to Yahoo Finance in Washington, D.C. The president’s chief economist tells us what’s open for negotiation and what’s not. Plus, our prophecy for posterity — or as we usually call it, the look ahead — for everything you need to know about tomorrow with your favorite interlocutor. Catch The Final Round at 3:55 p.m. with Jen Rogers and Yahoo Finance’s Myles Udland and Dan Roberts.
Biogen eyes therapies for Parkinson's, Alzheimer's and more using biomarkers, biological mechanisms and other cutting-edge technologies.
With an ROE of 28.62%, Biogen Inc (NASDAQ:BIIB) outpaced its own industry which delivered a less exciting 15.86% over the past year. While the impressive ratio tells us that BIIBRead More...
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $6.14 billion.
Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ...